Successful treatment of suspected early form of chronic Chagas cardiomyopathy: a case report

• Published in: European heart journal : case reports Vol. 6; no. 10
• Main Authors: Lu, Nelson, Werry, Denise, Chapman, Michael, Morshed, Muhammad, Ndao, Momar, Mirzanejad, Yazdan
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.10.2022
• Subjects: Atrial fibrillation; Canada; Cardiomyopathy; Care and treatment; Chagas' disease; Grand Round; Health aspects; Heart; Heart diseases; Heart failure; Mortality; Thromboembolism; Transplantation; Type 2 diabetes; Canada
• ISSN: 2514-2119; 2514-2119
• DOI: 10.1093/ehjcr/ytac403

Abstract Background Chagas disease, caused by the protozoan Trypanosoma cruzi, is the most common parasitic aetiology of non-ischaemic cardiomyopathy in the Americas, causing significant morbidity and mortality. The clinical spectrum ranges from early asymptomatic disease to severe cardiac manifestations including dilated cardiomyopathy, heart failure, dysrhythmias, conduction abnormalities, thromboembolism, and sudden death. Case summary We present a case of Chagas disease in a 75-year-old patient originally from El Salvador who presented to our Canadian tertiary centre with heart failure and atrial fibrillation/flutter. The patient had dilated cardiomyopathy with severely reduced systolic function, which was thought to be early Chagas cardiomyopathy after confirmatory positive serologies for T. cruzi. The patient demonstrated significant clinical improvement and recovery of systolic function with benznidazole therapy that was sustained up to 12 months on follow up. Discussion The American Heart Association recommends considering treatment of early chronic Chagas cardiomyopathy with anti-trypanosomal therapy. Our case highlights the importance of multidisciplinary collaboration in the diagnosis of early Chagas cardiomyopathy and critical timing of benznidazole, as effectiveness is limited in late disease due to myocardial cell-death programme. Although the historical BENEFIT study is known to not have shown mortality reduction, we advocate that the significant reduction in cardiovascular-related hospitalizations should be considered for symptomatic patients with early Chagas cardiomyopathy with the potential benefit of improving cardiac function and avoiding need for heart transplantation.